These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH; J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451 [No Abstract] [Full Text] [Related]
7. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Abrams CS; Cines DB Curr Hematol Rep; 2004 Mar; 3(2):143-7. PubMed ID: 14965491 [TBL] [Abstract][Full Text] [Related]
8. Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Weisman HF; Schaible TF; Jordan RE; Cabot CF; Anderson KM Biochem Soc Trans; 1995 Nov; 23(4):1051-7. PubMed ID: 8654680 [No Abstract] [Full Text] [Related]
9. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331 [TBL] [Abstract][Full Text] [Related]
10. Acute severe thrombocytopenia after treatment with ReoPro (abciximab). Butler R; Hubner PJ Heart; 2000 Apr; 83(4):E5. PubMed ID: 10722557 [TBL] [Abstract][Full Text] [Related]
11. Reversal of recurrent thrombocytopenia due to abciximab. Sharma V; Mascarenhas D J Invasive Cardiol; 2004 Sep; 16(9):537-8. PubMed ID: 15353816 [No Abstract] [Full Text] [Related]
13. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab. Nguyen N; Salib H; Mascarenhas DA J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690 [TBL] [Abstract][Full Text] [Related]
14. Acute profound thrombocytopenia following abciximab therapy. Bishara AI; Hagmeyer KO Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405 [TBL] [Abstract][Full Text] [Related]
15. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy. Rasti M; Blostein M Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241 [TBL] [Abstract][Full Text] [Related]
16. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off? Jeremias A; Gruberg L J Invasive Cardiol; 2009 Jun; 21(6):264-5. PubMed ID: 19494401 [No Abstract] [Full Text] [Related]
17. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621 [TBL] [Abstract][Full Text] [Related]
18. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors. Dunn A Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344 [No Abstract] [Full Text] [Related]
20. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Jeske WP; Walenga JM; Szatkowski E; Ero M; Herbert JM; Haas S; Bakhos M Thromb Res; 1997 Nov; 88(3):271-81. PubMed ID: 9526947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]